All News

13 October 2011

Emisphere Technologies, Inc. Reports Notification of First Interpretable Results on 2nd Phase III Study of Oral Calcitonin in Osteoarthritis PatientsAntibodies

11 October 2011

Study Shows That Roche’s Investigational Drug for Alzheimer’s Disease Removes Amyloid Plaques From the BrainAntibodies

11 October 2011

Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer PatientsAntibodies

10 October 2011

Daval International Announces Positive Phase II Results for AIMSPRO as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)Antibodies

6 October 2011

Peregrine Completes Patient Enrollment in Second-Line Non-Small Cell Lung Cancer Trial; Data to Be Unblinded in First Half 2012Antibodies

5 October 2011

iBio Announces Production of Biosimilar Rituximab with its iBioLaunch TechnologyAntibodies

4 October 2011

X-BODY Biosciences Enters Into R&D Partnership With Tanabe Research Laboratories U.S.A., Inc. to Generate Antibody Therapeutics for Autoimmune DisordersAntibodies

3 October 2011

MedImmune In-Licenses Cancer Immunotherapy Tremelimumab from PfizerAntibodies

30 September 2011

Circadian Files IND With FDA for VGX-100 for the Treatment of Cancer Patients With Solid TumorsAntibodies

29 September 2011

Lpath Initiates Dosing of iSONEP in First of Two Proof-of-Concept TrialsAntibodies

29 September 2011

Children’s Oncology Group and Apeiron to Jointly Conduct Phase II Study in Neuroblastoma With hu14.18-IL2 (APN301)Antibodies

27 September 2011

Novartis receives approval in Japan for two innovative therapies, Gilenya in MS and Ilaris in CAPSAntibodies

26 September 2011

Roche’s investigational medicine T-DM1 shows improvement in progression-free survival compared to standard of care in HER2-positive metastatic breast cancerAntibodies

26 September 2011

Abbott Japan and Eisai Submit Application in Japan for Additional Indication of Humira (adalimumab), a Fully Human Anti-TNF-± Monoclonal Antibody, for Inhibition of Structural Damage of Joints in Rheumatoid ArthritisAntibodies

26 September 2011

Peregrine Completes Patient Enrollment in Randomized Phase II HCV Trial for BavituximabAntibodies

26 September 2011

REMICADE Receives FDA Approval as First Biologic Treatment for Pediatric Ulcerative ColitisAntibodies

26 September 2011

Impact of CATT Study Findings Evident in Significant Reported Changes in Prescribing of Genentech’s Avastin and Lucentis for the Treatment of Wet AMD According to a BioTrends ReportAntibodies

23 September 2011

Alexion Receives CHMP Positive Opinion for Soliris (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS) in the European UnionAntibodies

23 September 2011

Immunomedics Announces Partial Clinical Hold on Clivatuzumab Tetraxetan Clinical TrialAntibodies

23 September 2011

ImmunoGen, Inc. Announces Submission of IND for Wholly Owned Product Candidate for Non-Hodgkin’s LymphomaAntibodies

22 September 2011

NovImmune initiates a Proof-of-Concept study in Primary Biliary Cirrhosis (PBC)Antibodies

21 September 2011

Theraclone Sciences Announces Initiation of Phase 1 Clinical Trial of TCN-032 for Influenza AAntibodies

21 September 2011

Glycotope Enrolls First Patients in Phase I Trial with TrasGEX, a Glycooptimized HER2 Biobetter AntibodyAntibodies

21 September 2011

Bristol-Myers Squibb and Ono Enter into Strategic Agreement for Anti-PD-1 Antibody, BMS-936558/ONO-4538, and ORENCIA (abatacept)Antibodies

21 September 2011

New study finds rheumatoid arthritis (RA) patients preferred ergonomically designed Cimzia (certolizumab pegol) syringe to conventional prefilled syringeAntibodies

20 September 2011

Fresenius Biotech’s Removab receives approval for a shorter infusion time in treating malignant ascitesAntibodies

19 September 2011

Prolia (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of TreatmentAntibodies

19 September 2011

FDA Approves New Indications for Prolia (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation TherapyAntibodies

16 September 2011

Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood ArthritisAntibodies

15 September 2011

Phase 2 Study of Eculizumab (Soliris) in Patients with Severe and Refractory Generalized Myasthenia Gravis Presented at MGFA Annual MeetingAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

PD-1 x VEGF and PD-L1 x VEGF bispecific antibodies: a business, pipeline and competitor analysis from an industry perspective

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

CCR8-Targeted Antibody Immunotherapy Pipeline Review

Ustekinumab (Stelara) Biosimilars Pipeline Review

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Mesothelin-Targeted Immunotherapy Pipeline Review

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Report Package: “Drug the Undruggable” Technologies

CD38-Targeted Antibody & Cell Therapy Pipeline Review